JAK inhibitors can block the TGF-β-mediated STAT protein activation pathway by inhibiting autophagy, thereby inhibiting fibrosis in the skin of SSc patients and achieving the treatment of SSc (193). This evidence concerns the gene SOAT1 and systemic sclerosis.